Efficacy of sofosbuvir and daclatasvir in compensated chronic hepatitis C infection
A single center, open-label and proof of concept study
Keywords:
sofosbuvir and daclatasvir, hepatitis C, infectionAbstract
Aims and objectives: The advent of directly acting agents for the treatment of Hepatitis C infection has forever transformed our understanding and management of viral infections. With over 95 % patients achieving a sustained viral response at 12 weeks with some of these newly inducted agents, the prospect of eradicating the Hepatitis C virus seems like an achievable target, which makes this one of the most important discoveries in modern medicine. We studied the combination of Sofosbuvir and Daclatasvir in patients with chronic hepatitis C infection (Genotype 3) to assess the rates of sustained virological response at 12 weeks. Methods: We studied 67 treatment naive patients with compensated chronic hepatitis C infection (genotype 3). They were all started on Tab Sofosbuvir 400 mg daily and Tab Daclatasvir 60 mg once daily for 12 weeks and followed up for a total of 24 weeks, which includes a treatment duration and observation period of 12 weeks each. The patients were monitored with HCV RNA levels at one, three and six months, with as many evaluations of liver function and routine hemogram.
Downloads
References
Abraham P. Treatment for hepatitis C virus infection in India: Promising times. Indian J Med Microbiol. 2016;34(3):273-4.
Akbarov, A. N., & Xabilov, D. N. U. (2021). The condition of the oral cavity in patients who have had a viral infection COVID-19. International Journal of Health & Medical Sciences, 4(4), 381-383. https://doi.org/10.21744/ijhms.v4n4.1796
Armand M, Besson C, Hermine O, Davi F. Hepatitis C virus - Associated marginal zone lymphoma. Best Pract Res Clin Haematol. 2017;30(1-2):41-9.
Asselah T. Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy. J Hepatol. 2014;61(2):435-8.
ASSESSMENT OF HCV TREATMENT RESPONSE - test of cure. WHO Guidelines on Hepatitis B and C Testing. WHO Guidelines Approved by the Guidelines Review Committee. Geneva2017.
Bari K, Sharma P. Combination of daclatasvir and sofosbuvir for hepatitis C genotypes 1, 2, and 3. Gastroenterology. 2014;147(2):534-6.
Bhagat VH, Sepe T. Pancreatic lymphoma complicating early stage chronic hepatitis C. BMJ Case Rep. 2017;2017.
Couronne L, Bachy E, Roulland S, Nadel B, Davi F, Armand M, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol. 2018;29(1):92-100.
Daneshvar M, Nikbin M, Talebi S, Javadi F, Aghasadeghi MR, Mahmazi S, et al. Role of IL28-B Polymorphism (rs12979860) on Sustained Virological Response to Pegylated Interferon/Ribavirin in Iranian Patients With Chronic Hepatitis C. Iran Red Crescent Med J. 2016;18(9):e28566.
Dedania B, Wu GY. Dermatologic Extrahepatic Manifestations of Hepatitis C. J Clin TranslHepatol. 2015;3(2):127-33.
Degasperi E, Aghemo A, Colombo M. Treatment of Extrahepatic Manifestations of Hepatitis C Virus. Clin Liver Dis. 2017;21(3):631-43.
Dhaliwal HS, Nampoothiri RV. Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med. 2014;370(16):1560.
Dhiman RK, Satsangi S, Grover GS, Puri P. Tackling the Hepatitis C Disease Burden in Punjab, India. J Clin Exp Hepatol. 2016;6(3):224-32.
Espinoza-Rios J, Valenzuela Granados V, Ojeda Cisneros M, Galvez Canseco A, Ramos Aguilar C, Raymundo Villalva B, et al. [Porphyria cutanea tarda as extrahepatic manifestation of chronic hepatitis C: a case report]. Rev Gastroenterol Peru. 2017;37(4):394-8.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Fauvelle C, Felmlee DJ, Baumert TF. Unraveling hepatitis C virus structure. Cell Res. 2014;24(4):385-6.
Flores-Chavez A, Carrion JA, Forns X, Ramos-Casals M. Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. Rev EspSanidPenit. 2017;19(3):87-97.
Forns X, Berenguer M, Herzer K, Sterneck M, Donato MF, Andreone P, et al. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Transpl Infect Dis. 2017;19(3).
Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10(12):1363-77.
Gupta S, Tehami N, Tarn A. Extrahepatic manifestations of hepatitis C. Frontline Gastroenterol. 2014;5(3):224.
Hernandez D, Yu F, Huang X, Kirov S, Pant S, McPhee F. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Adv Ther. 2016;33(7):1169-79.
Iliescu L, Mercan-Stanciu A, Ioanitescu ES, Toma L. Hepatitis C-Associated B- cell Non-Hodgkin Lymphoma: A Pictorial Review. Ultrasound Q. 2018;34(3):156-66.
Indol G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr. 2013;163(6):1549-52 e1.
Kahveci AM, Tahan V. Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies. Turk J Gastroenterol. 2016;27(1):89-90.
Kai Y, Hikita H, Tatsumi T, Nakabori T, Saito Y, Morishita N, et al. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol. 2015;50(11):1145-51.
Khemichian S, Lee B, Kahn J, Noureddin M, Kim B, Harper T, et al. Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation. Transplant Direct. 2015;1(6):e21.
Kristensen O, Rysstad O, Gallefoss F. [Short-time hepatitis C treatment and drug abuse]. Tidsskr Nor Laegeforen. 2009;129(23):2498; author reply 9.
Labie D, Gilgenkrantz H. [IL28 (interferon lambda3) gene polymorphismsand response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci (Paris). 2010;26(3):225-6.
Lee SS, Kim CY, Kim BR, Cha RR, Kim WS, Kim JJ, et al. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea. J Viral Hepat. 2018.
Liang TJ, Terrault N. Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2018.
Manzano-RobledaMdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta- analysis. Ann Hepatol. 2015;14(1):46-57.
Marrero-Alvarez P, Gil-Gomez I, Monte-Boquet E, Lorente-Fernandez L, Poveda-Andres JL. [Boceprevir and telaprevir utilization: evaluation for the treatment of chronic hepatitis C]. Farm Hosp. 2014;38(1):30-7.
Miuma S, Ichikawa T, Miyaaki H, Haraguchi M, Tamada Y, Shibata H, et al. Efcacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. J Interferon Cytokine Res. 2016;36(6):358-66.
Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol. 2013;369:113-42.
Negro F, Esmat G. Extrahepatic manifestations in hepatitis C virus infection. J Adv Res. 2017;8(2):85-7.
Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345-60.
Panel A-IHG. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2018;67(10):1477-92.
Park C, Jiang S, Lawson KA. Efcacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis. J Clin Pharm Ther. 2014;39(1):14-24.
Pedergnana V, Smith D, Consortium S-H, Klenerman P, Barnes E, Spencer CC, et al. Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a. Hepatology. 2016;64(4):1377-8.
Ponzetto A, Carloni G. Hepatitis C virus and lymphoma. Hepatology. 2016;64(5):1813.
Powderly WG, Naggie S, Kim AY, Vargas HE, Chung RT, Lok AS. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clin Infect Dis. 2017;65(11):1773-5.
Rizk NM, Derbala MF. Genetic polymorphisms of ICAM 1 and IL28 as predictors of liver fibrosis severity and viral clearance in hepatitis C genotype4 Clin Res Hepatol Gastroenterol. 2013;37(3):262-8.
Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24(4-5):469-82.
Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant. 2018;8(4):84-96.
Sherman AC, Sherman KE. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep. 2015;12(3):353-61.
Sood A, Midha V, Bansal M, Sood N, Puri S, Thara A. Perinatal transmission of hepatitis C virus in northern India. Indian J Gastroenterol. 2012;31(1):27-9.
Sood A, Suryaprasad A, Trickey A, Kanchi S, Midha V, Foster MA, et al. The burden of hepatitis C virus infection in Punjab, India: A population-based serosurvey. PLoS One. 2018;13(7):e0200461.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Tanaka T, Akamatsu N, Kaneko J, Arita J, Tamura S, Hasegawa K, et al. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection. Hepatol Res. 2016;46(8):829-32.
Terrault NA. Care of Patients Following Cure of Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2018;14(11):629-34.
Testino G, Leone S, Fagoonee S. Hepatitis C virus, alcohol use disorders and hepatocellular carcinoma. Panminerva Med. 2018.
Toniutto P. [Hepatitis C virus infection. From clinical guidelines to clinical practice and personalization of cure.]. Recenti Prog Med. 2018;109(1):33-7.
Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9(11):e112647.
Yoshimi S, Ochi H, Murakami E, Uchida T, Kan H, Akamatsu S, et al. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. PLoS One. 2015;10(6):e0130022.
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology. 2016;150(7):1599-608.
Zhang T, Li Y, Ho WZ. Drug abuse, innate immunity and hepatitis C virus. Rev Med Virol. 2006;16(5):311-27.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
